DK3448430T3 - Anvendelse af en acetylcholinesterase-inhibitor og idalopirdin til reduktion af fald hos patienter med parkinsons sygdom - Google Patents

Anvendelse af en acetylcholinesterase-inhibitor og idalopirdin til reduktion af fald hos patienter med parkinsons sygdom Download PDF

Info

Publication number
DK3448430T3
DK3448430T3 DK17719255.6T DK17719255T DK3448430T3 DK 3448430 T3 DK3448430 T3 DK 3448430T3 DK 17719255 T DK17719255 T DK 17719255T DK 3448430 T3 DK3448430 T3 DK 3448430T3
Authority
DK
Denmark
Prior art keywords
idalopirdine
parkinson
patients
disease
acetylcholinesterase inhibitor
Prior art date
Application number
DK17719255.6T
Other languages
English (en)
Inventor
Jong Inge E M De
Martin Sarter
Aaron Kucinski
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of DK3448430T3 publication Critical patent/DK3448430T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17719255.6T 2016-04-26 2017-04-25 Anvendelse af en acetylcholinesterase-inhibitor og idalopirdin til reduktion af fald hos patienter med parkinsons sygdom DK3448430T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201600248 2016-04-26
PCT/EP2017/059739 WO2017186686A1 (en) 2016-04-26 2017-04-25 Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients

Publications (1)

Publication Number Publication Date
DK3448430T3 true DK3448430T3 (da) 2023-07-03

Family

ID=58632402

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17719255.6T DK3448430T3 (da) 2016-04-26 2017-04-25 Anvendelse af en acetylcholinesterase-inhibitor og idalopirdin til reduktion af fald hos patienter med parkinsons sygdom

Country Status (28)

Country Link
US (1) US10383849B2 (da)
EP (1) EP3448430B1 (da)
JP (1) JP6992004B2 (da)
KR (1) KR102473545B1 (da)
CN (3) CN118806910A (da)
AU (1) AU2017256623B2 (da)
BR (1) BR112017026928B1 (da)
CA (1) CA3020557C (da)
CL (1) CL2018003013A1 (da)
CY (1) CY1126138T1 (da)
DK (1) DK3448430T3 (da)
ES (1) ES2949288T3 (da)
FI (1) FI3448430T3 (da)
HR (1) HRP20230693T8 (da)
HU (1) HUE062626T2 (da)
IL (1) IL262546B (da)
LT (1) LT3448430T (da)
MX (1) MX387444B (da)
PL (1) PL3448430T3 (da)
PT (1) PT3448430T (da)
RS (1) RS64307B1 (da)
RU (1) RU2742173C2 (da)
SG (1) SG11201809297UA (da)
SI (1) SI3448430T1 (da)
SM (1) SMT202300197T1 (da)
TW (1) TW201806621A (da)
WO (1) WO2017186686A1 (da)
ZA (1) ZA201806864B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61704B1 (sr) 2017-05-24 2021-05-31 H Lundbeck As Kombinacija antagonista 5-ht6 receptora i inhibitora acetilholinesteraze za upotrebu u lečenju alchajmerove bolesti kod subpopulacije pacijenata koji nose apoe4 alele
EP3727043B1 (en) * 2017-12-22 2026-06-10 Golden Gait Biotech, S.L. Nicotine for use in reducing frequency of falls in subjects with parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818914D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
JP5180816B2 (ja) * 2005-04-04 2013-04-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患および認知症のためのジヒドロピリジン化合物
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
JP2009541423A (ja) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と5‐ht6レセプター親和性の化合物との組合せ
EP2254564A1 (en) * 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
RU2393158C1 (ru) * 2008-10-06 2010-06-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
US20170304267A1 (en) 2017-10-26
SI3448430T1 (sl) 2023-08-31
EP3448430A1 (en) 2019-03-06
US10383849B2 (en) 2019-08-20
AU2017256623A1 (en) 2018-11-01
RU2018135846A3 (da) 2020-09-30
CN118806909A (zh) 2024-10-22
CA3020557C (en) 2024-05-21
SMT202300197T1 (it) 2023-09-06
CN118806910A (zh) 2024-10-22
JP2019519480A (ja) 2019-07-11
WO2017186686A1 (en) 2017-11-02
HRP20230693T8 (hr) 2023-11-10
CN109069650A (zh) 2018-12-21
PL3448430T3 (pl) 2023-08-21
IL262546B (en) 2022-05-01
EP3448430B1 (en) 2023-06-07
RU2742173C2 (ru) 2021-02-02
CL2018003013A1 (es) 2018-12-14
PT3448430T (pt) 2023-07-11
KR102473545B1 (ko) 2022-12-01
ES2949288T3 (es) 2023-09-27
RU2018135846A (ru) 2020-05-26
BR112017026928A2 (pt) 2018-08-14
AU2017256623B2 (en) 2022-07-21
LT3448430T (lt) 2023-07-25
BR112017026928B1 (pt) 2023-04-11
HUE062626T2 (hu) 2023-11-28
TW201806621A (zh) 2018-03-01
ZA201806864B (en) 2020-01-29
IL262546A (en) 2018-12-31
SG11201809297UA (en) 2018-11-29
MX2018013031A (es) 2019-01-17
JP6992004B2 (ja) 2022-02-03
KR20180133869A (ko) 2018-12-17
CY1126138T1 (el) 2023-11-15
RS64307B1 (sr) 2023-07-31
HRP20230693T1 (hr) 2023-10-13
MX387444B (es) 2025-03-18
FI3448430T3 (fi) 2023-06-20
CA3020557A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
DK4014976T3 (da) Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan
DK3405215T3 (da) Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser
DK3352584T3 (da) Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe
DK3335709T3 (da) Gamma-hydroxybutyratsammensætninger og deres anvendelse til behandling af lidelser
DK3672954T3 (da) Forbindelser og salte deraf og deres anvendelse til behandling af sygdomme
DK3169403T3 (da) Orale peptidinhibitorer af interleukin-23-receptor og deres anvendelse til behandling af inflammatoriske tarmsygdomme
DK3209302T3 (da) Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom
PL3402888T3 (pl) Środki i sposoby leczenia hbv
DK3381451T3 (da) Farmaceutisk sammensætning brugt til at reducere lokaliseret fedt samt brug af den farmaceutiske sammensætning
DK3233130T3 (da) Nukleinsyrekonstruktioner og genterapivektorer til anvendelse i behandlingen af wilson-sygdom
DK3676285T3 (da) Vaccine til anvendelse i profylakse og/eller behandling af en sygdom
DK3371152T3 (da) Sammensætninger omfattende en hæmmer af lysinspecifik demethylase-1 med en pyrimidinring og anvendelse deraf i behandling af cancer
DK3372229T3 (da) Fremgangsmåder til øgning af tonisk hæmning og behandling af angelmans syndrom
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
DK3512517T3 (da) Anvendelse af pridopidin til behandling af angst og depression
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3388427T3 (da) Derivater af dolastatin 10 og auristatiner
DK3386523T3 (da) Bifidobacterium longum til behandling af fedme og associerede metabolske sygdomme
DK3643321T3 (da) Plasminogen til anvendelse i behandling af parkinsons og alzheimers sygdom
IL271464A (en) Nk-1 antagonist compositions and methods for use in treating depression
DK3463308T3 (da) Formuleringer af polyalkylenoxid-asparaginase og fremgangsmåder til fremstilling og anvendelse deraf
DK3722291T3 (da) Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme
SI3204030T1 (sl) Kombinirano zdravljenje okužbe s HBV in HDV
DK3440752T3 (da) Indsatshalvdel og indsatsblok omfattende to af nævnte indsatshalvdele
DK3444010T3 (da) Pklr-inhibering i behandlingen af nafld og hcc